View Post

Patient Selection Takes Priority as Standard of Cares Shift in HR+ and HER2+ Breast Cance

In In The News by Barbara Jacoby

By: Ashling Wahner From: onclive.com With the array of CDK4/6 inhibitors available for patients with hormone receptor (HR)–positive breast cancer, treatment optimization according to patient characteristics is crucial, according to Lauren E. Nye, MD, who added that additional treatments are on the horizon for patients with brain metastases. In an interview with OncLive® following a State of the Science Summit™ …

View Post

Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer

In In The News by Barbara Jacoby

By: Caroline Helwick From: ascopost.com Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to their pharmacokinetics or toxicity profiles, which allow for ligand-independent estrogen receptor signaling as a mechanism of resistance. Novel endocrine approaches to addressing treatment resistance, with a focus …

View Post

Exploring the potential of statins in reducing breast cancer mortality

In In The News by Barbara Jacoby

By: D Moosavi From: fredhutch.org Statins work like a vigilant janitor: they block an enzyme in the liver that produces cholesterol, much like a janitor might simply turn off a leaky faucet to prevent a room from flooding. Statins are firmly established in cardiovascular medicine for preventing heart attacks and strokes because they reduce cholesterol. Now, what is even more …

View Post

Study reveals lasting quality of life inequities in breast cancer patients

In In The News by Barbara Jacoby

Source: University of Geneva From: news-medical.net When it comes to health, inequalities can be seen at every level for women with breast cancer: prevention, screening, diagnosis, treatment, and survival. But what about their quality of life? A team from the University of Geneva (UNIGE), the University Hospitals of Geneva (HUG), Inserm, and Gustave Roussy has tracked nearly 6,000 women diagnosed …

View Post

Advancements in HER2-Directed Therapies Abound for HER2+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Ashling Wahner From: onclive.com As the role of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) expands for patients with metastatic HER2-positive breast cancer and novel antibody-drug conjugates (ADCs) enter the scene, increasing familiarity with these agents can optimize treatment outcomes and minimize toxicities, according to Aditya Bardia, MD, MPH, FASCO. “It’s an exciting paradigm in terms of newer therapies that are coming …

View Post

Team highlights long-term impact of socioeconomic inequalities on quality of life for women after breast cancer

In In The News by Barbara Jacoby

By: University of Geneva From: medicalxpress.com When it comes to health, inequalities can be seen at every level for women with breast cancer: prevention, screening, diagnosis, treatment, and survival. But what about their quality of life? A team from the University of Geneva (UNIGE), the University Hospitals of Geneva (HUG), Inserm, and Gustave Roussy has tracked nearly 6,000 women diagnosed …

View Post

Researchers discover promising approach to prevent recurrence of breast cancer

In In The News by Barbara Jacoby

By: University of Turku From: medicalxpress.com Treatment outcomes for breast cancer have become better over the years, but a proportion of breast cancers still recur even after long periods without signs of cancer remaining dormant in the body. Finnish cancer researchers have discovered a mechanism that wakes up these dormant breast cancer cells and demonstrated that preventing the mechanism can …

View Post

Study Documents Decline in Reimbursements for Breast Cancer Surgery From 2003 to 2023

In In The News by Barbara Jacoby

By: Caroline Helwick From: ascopost.com Over the past 20 years, Medicare reimbursements for 10 breast cancer surgical procedures rose by 22%, but inflation rose three times as much—by 69%. Compared with the financial picture had rates kept pace with inflation, the result is an estimated aggregate loss of more than $100 million for breast cancer surgeons, researchers reported at the …